Expression of Histone Deacetylases HDAC1, HDAC2, HDAC3, and HDAC6 in Invasive Ductal Carcinomas of the Breast.
10.4048/jbc.2014.17.4.323
- Author:
Jinwon SEO
1
;
Soo Kee MIN
;
Hye Rim PARK
;
Dong Hoon KIM
;
Mi Jung KWON
;
Lee Su KIM
;
Young Su JU
Author Information
1. Department of Pathology, Hallym University Sacred Heart Hospital, Hallym University College of Medicine, Anyang, Korea. tgmsk@hallym.ac.kr
- Publication Type:In Vitro ; Original Article
- Keywords:
Breast neoplasms;
Histone deacetylases;
Immunohistochemistry
- MeSH:
Breast Neoplasms;
Breast*;
Carcinogenesis;
Carcinoma, Ductal*;
Cohort Studies;
Disease-Free Survival;
DNA;
Epidermal Growth Factor;
Estrogens;
Histone Deacetylase Inhibitors;
Histone Deacetylases*;
Humans;
Immunohistochemistry;
Multivariate Analysis;
Phenobarbital;
Receptors, Progesterone
- From:Journal of Breast Cancer
2014;17(4):323-331
- CountryRepublic of Korea
- Language:English
-
Abstract:
PURPOSE: DNA deacetylation by histone deacetylase (HDAC) is an important mechanism involved in the oncogenic tumorigenesis of breast cancer. Previous studies have reported an association of the estrogen receptor (ER) with HDACs and demonstrated the efficacy of HDAC inhibitors for the treatment of breast cancers via in vitro experiments. In this study, we examined the association of HDAC expression with clinicopathological parameters and disease-specific survival. METHODS: Immunohistochemical (IHC) analysis of HDAC1, HDAC2, HDAC3, and HDAC6 was performed using tissue microarrays in 300 invasive ductal carcinomas. IHC scoring was determined by multiplication of the intensity (0 to 3) and the proportion (0 to 4) of staining, and we classified tumors into low- and high-HDAC expression groups. RESULTS: High expression of HDAC1 was correlated with the molecular subtype (p=0.001) and human epidermal growth factor 2 (HER2) amplification (p=0.012). High expression of HDAC6 was correlated with a younger age (p<0.001), ER expression (p=0.025), progesterone receptor expression (p=0.034), molecular subtype (p=0.023), and HER2 amplification (p=0.011). High HDAC1 expression was correlated with luminal A tumors (p=0.001), while high HDAC6 expression was more common in luminal B tumors (p=0.023). Although the expression of HDACs did not exhibit prognostic significance in the entire cohort, high expression of HDAC1 and HDAC6 was associated with improved overall survival (OS) in patients with ER-positive tumors (p=0.017 and p=0.029, respectively), and high expression of HDAC2 was correlated with improved OS in ER-negative tumors (p=0.048) on univariate analysis. Furthermore, high HDAC6 expression was associated with improved disease-free survival (p=0.048) on multivariate analysis. CONCLUSION: HDAC1 expression is significantly correlated with the molecular subtypes of tumors, with the highest expression being observed in luminal A tumors. HDAC6 is a significantly correlated with ER expression and the molecular subtype, thereby supporting the estrogen regulatory property of HDAC6. HDAC1 and HDAC6 expression are good prognostic factors for ER-positive tumors.
